It has been highlighted that the original article [1] contains an error in Fig. 3 specifically, that it showed an incorrect version of Fig. 3c. This does not affect the Figure legend, results and conclusions of the article. The correct version of Fig. 3 is shown in this Correction article.
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.